1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Marketwired
Marketwired
Articles 

Detailed Research: Economic Perspectives on Novartis AG, Proteostasis Therapeutics, Williams-Sonoma, Magna International, YRC Worldwide, and Delek Logistics Partners — What Drives Growth in Today's Competitive Landscape

February 25, 2019 | About:

NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Novartis AG (:NVS), Proteostasis Therapeutics, Inc. (NASDAQ:PTI), Williams-Sonoma, Inc. (:WSM), Magna International Inc. (:MGA), YRC Worldwide, Inc. (NASDAQ:YRCW), and Delek Logistics Partners, L.P. (:DKL), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

NVS DOWNLOAD: http://MarketSourceResearch.com/register/?so=NVS
PTI DOWNLOAD: http://MarketSourceResearch.com/register/?so=PTI
WSM DOWNLOAD: http://MarketSourceResearch.com/register/?so=WSM
MGA DOWNLOAD: http://MarketSourceResearch.com/register/?so=MGA
YRCW DOWNLOAD: http://MarketSourceResearch.com/register/?so=YRCW
DKL DOWNLOAD: http://MarketSourceResearch.com/register/?so=DKL

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine Novartis AG (:NVS), Proteostasis Therapeutics, Inc. (NASDAQ:PTI), Williams-Sonoma, Inc. (:WSM), Magna International Inc. (:MGA), YRC Worldwide, Inc. (NASDAQ:YRCW), and Delek Logistics Partners, L.P. (:DKL) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 22nd, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

NOVARTIS AG (NYSE:NVS) REPORT OVERVIEW

Novartis AG's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Novartis AG reported revenue of $13,664.00MM vs $13,164.00MM (up 3.80%) and analysts estimated basic earnings per share $0.53 vs $0.85 (down 37.65%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Novartis AG reported revenue of $53,166.00MM vs $50,135.00MM (up 6.05%) and analysts estimated basic earnings per share $5.44 vs $3.28 (up 65.85%). Analysts expect earnings to be released on April 18th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.28. The estimated EPS forecast for the next fiscal year is $6.01 and is expected to report on January 29th, 2020.

To read the full Novartis AG (NYSE:NVS) report, download it here: http://MarketSourceResearch.com/register/?so=NVS

-----------------------------------------

PROTEOSTASIS THERAPEUTICS, INC. (NASDAQ:PTI) REPORT OVERVIEW

Proteostasis Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Proteostasis Therapeutics reported revenue of $1.06MM vs $1.55MM (down 31.98%) and analysts estimated basic earnings per share -$0.50 vs -$0.56. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Proteostasis Therapeutics reported revenue of $5.34MM vs $8.38MM (down 36.30%) and analysts estimated basic earnings per share -$2.34 vs -$2.06. Analysts expect earnings to be released on March 13th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.51. The estimated EPS forecast for the next fiscal year is -$2.10 and is expected to report on March 13th, 2019.

To read the full Proteostasis Therapeutics, Inc. (NASDAQ:PTI) report, download it here: http://MarketSourceResearch.com/register/?so=PTI

-----------------------------------------

WILLIAMS-SONOMA, INC. (NYSE:WSM) REPORT OVERVIEW

Williams-Sonoma's Recent Financial Performance

For the three months ended October 31st, 2018 vs October 31st, 2017, Williams-Sonoma reported revenue of $1,356.98MM vs $1,299.34MM (up 4.44%) and analysts estimated basic earnings per share $1.01 vs $0.84 (up 20.24%). For the twelve months ended January 31st, 2018 vs January 31st, 2017, Williams-Sonoma reported revenue of $5,292.36MM vs $5,083.81MM (up 4.10%) and analysts estimated basic earnings per share $3.03 vs $3.45 (down 12.17%). Analysts expect earnings to be released on March 13th, 2019. The report will be for the fiscal period ending January 31st, 2019. Reported EPS for the same quarter last year was $1.68. The estimated EPS forecast for the next fiscal year is $4.45 and is expected to report on March 13th, 2019.

To read the full Williams-Sonoma, Inc. (NYSE:WSM) report, download it here: http://MarketSourceResearch.com/register/?so=WSM

-----------------------------------------

MAGNA INTERNATIONAL INC. (NYSE:MGA) REPORT OVERVIEW

Magna International's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Magna International reported revenue of $9,618.00MM vs $8,864.00MM (up 8.51%) and basic earnings per share $1.63 vs $1.39 (up 17.27%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Magna International reported revenue of $38,946.00MM vs $36,445.00MM (up 6.86%) and analysts estimated basic earnings per share $5.93 vs $5.19 (up 14.26%). Analysts expect earnings to be released on May 9th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.84. The estimated EPS forecast for the next fiscal year is $7.68 and is expected to report on February 28th, 2020.

To read the full Magna International Inc. (NYSE:MGA) report, download it here: http://MarketSourceResearch.com/register/?so=MGA

-----------------------------------------

YRC WORLDWIDE, INC. (NASDAQ:YRCW) REPORT OVERVIEW

YRC Worldwide's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, YRC Worldwide reported revenue of $1,247.40MM vs $1,208.60MM (up 3.21%) and analysts estimated basic earnings per share $0.52 vs -$0.22. For the twelve months ended December 31st, 2018 vs December 31st, 2017, YRC Worldwide reported revenue of $5,092.00MM vs $4,891.00MM (up 4.11%) and analysts estimated basic earnings per share $0.61 vs -$0.33. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.44. The estimated EPS forecast for the next fiscal year is $1.00 and is expected to report on January 30th, 2020.

To read the full YRC Worldwide, Inc. (NASDAQ:YRCW) report, download it here: http://MarketSourceResearch.com/register/?so=YRCW

-----------------------------------------

DELEK LOGISTICS PARTNERS, L.P. (NYSE:DKL) REPORT OVERVIEW

Delek Logistics Partners' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Delek Logistics Partners reported revenue of $164.11MM vs $130.63MM (up 25.63%) and analysts estimated basic earnings per share $0.68 vs $0.50 (up 36.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Delek Logistics Partners reported revenue of $538.08MM vs $448.06MM (up 20.09%) and analysts estimated basic earnings per share $2.09 vs $2.08 (up 0.48%). Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.59. The estimated EPS forecast for the next fiscal year is $3.13 and is expected to report on February 18th, 2020.

To read the full Delek Logistics Partners, L.P. (NYSE:DKL) report, download it here: http://MarketSourceResearch.com/register/?so=DKL

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at [email protected]

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: [email protected]

© 2019 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.


ti?nf=NzU0ODQyMiMyNzk2Njc0IzUwMDAzMTMyNg

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by Marketwired


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK